Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies;Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies;Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies;Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 1;Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 22;Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine and COVID-19 Vaccine Antibodies;Number of Participants With Immediate Unsolicited Adverse Events (AEs);Number of Participants With Medically Attended Adverse Events (MAAEs);Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs);Number of Participants With Solicited Injection Site Reactions;Number of Participants With Solicited Systemic Reactions;Number of Participants With Unsolicited Adverse Events;Percentage of Participants Achieving Seroconversion Against Influenza and COVID-19 Virus Antigens;Percentage of Participants With >=2-Fold and >=4-Fold Rise in Anti-S Binding IgG Antibodies;Percentage of Participants With Antibody Titers >=40 (1/Dilution);Percentage of Participants With Antibody Titers >=40 (1/Dilution);Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution);Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies;Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies;Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies;Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 1;Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 22;Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine and COVID-19 Vaccine Antibodies;Number of Participants With Immediate Unsolicited Adverse Events (AEs);Number of Participants With Medically Attended Adverse Events (MAAEs);Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs);Number of Participants With Solicited Injection Site Reactions;Number of Participants With Solicited Systemic Reactions;Number of Participants With Unsolicited Adverse Events;Percentage of Participants Achieving Seroconversion Against Influenza and COVID-19 Virus Antigens;Percentage of Participants With >=2-Fold and >=4-Fold Rise in Anti-S Binding IgG Antibodies;Percentage of Participants With Antibody Titers >=40 (1/Dilution);Percentage of Participants With Antibody Titers >=40 (1/Dilution);Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution);Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

2-fold-rise in anti-S binding IgG concentration;4-fold-rise in anti-S binding IgG concentration;Hemagglutination inhibition (HAI) individual titer;Individual anti-S binding IgG concentration;Individual anti-S binding IgG concentration ratio D22/D01;Individual HAI titers ratio D22/D01;Number of participants with immediate adverse events (AEs);Number of participants with influenza vaccine antibody titer ≥ 10;Number of participants with influenza vaccine antibody titer ≥ 40;Number of participants with medically attended adverse events (MAAE)s;Number of participants with serious adverse events (SAEs) and Adverse Events of Special Interest (AESIs);Number of participants with seroconversion;Number of participants with solicited injection site reactions or systemic reactions;Number of participants with unsolicited AEs

2-fold-rise in anti-S binding IgG concentration;4-fold-rise in anti-S binding IgG concentration;Hemagglutination inhibition (HAI) individual titer;Individual anti-S binding IgG concentration;Individual anti-S binding IgG concentration ratio D22/D01;Individual HAI titers ratio D22/D01;Number of participants with immediate adverse events (AEs);Number of participants with influenza vaccine antibody titer ≥ 10;Number of participants with influenza vaccine antibody titer ≥ 40;Number of participants with medically attended adverse events (MAAE)s;Number of participants with serious adverse events (SAEs) and Adverse Events of Special Interest (AESIs);Number of participants with seroconversion;Number of participants with solicited injection site reactions or systemic reactions;Number of participants with unsolicited AEs